• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

How Sanofi blew its chance with Actelion

February 16, 2017 By Sarah Faulkner

How Sanofi blew its chance with ActelionDays before entering into exclusive takeover negotiations with Johnson & Johnson (NYSE:JNJ), Actelion (VTX:ATLN) was reportedly fielding an offer from Sanofi (NYSE:SNY). But the Swiss biotech eventually agreed to go with J&J’s $30 billion bid in an all-cash deal at the end of January.

Actelion accepted the U.S. healthcare giant’s offer because it provided more certainty, Reuters reported today.

The prospectus for J&J’s offer revealed that the rival bidder, previously identified as Sanofi, made a proposal that outbid J&J’s offer. But Sanofi later refused to proceed with takeover talks unless Actelion considered a lower price, the news outlet reported.

“Company A indicated that it would only be willing to proceed with a transaction on the basis of a price lower than its previously communicated offer price and on different terms,” the prospectus said.

Actelion’s board discussed the 2 offers on Jan. 23, according to Reuters, and ultimately decided that although the financial terms of the competing proposals would bring equal value to shareholders, J&J’s offer provided more certainty.

“J&J’s proposal offered significantly greater transaction certainty because the transaction documentation was nearly final and because J&J had already completed the required due diligence,” the board concluded.

The companies plan to spin off Actelion’s research and development pipeline into a new company, led by Actelion CEO Jean-Paul Clozel.

J&J’s prospectus provided details into how the new company will be financed, including a a credit facility worth $250 million and a 10-year convertible loan worth 580 million Swiss francs from J&J, as well as 420 million Swiss francs provided by Actelion.

The new company plans to list on the SIX Swiss Exchange, according to Reuters.

Analysts expected Sanofi to compete eagerly for Actelion, since it lost out on a deal to buy Medivation Inc. last year, giving competitor Pfizer (NYSE:PFE) a blockbuster prostate cancer treatment.

At the time, CEO Olivier Brandicourt said that Sanofi would be ready to “act rather swiftly” should a new opportunity for an acquisition arise.

Materials from Reuters were used in this report.

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Pfizer Inc., Sanofi-Aventis

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS